Syed Haider

Dr. Syed Haider

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DZDiana Zatreanu
Diana Zatreanu
HRHelen M. R. Robinson
Helen M. R. Robinson
OAOmar Alkhatib
Omar Alkhatib
MBMarie Boursier
Marie Boursier
HFHarry Finch
Harry Finch
CLChristopher J. Lord
Christopher J. Lord
To identify approaches to target DNA repair vulnerabilities in cancer, we discovered nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the polymerase function of DNA polymerase Polθ, including ART558. ART558 inhibits the major Polθ-mediated DNA repair process, Theta-Mediated End Joining, without targeting Non-Homologous End Joining. In addition, ART558 elicits DNA damage and synthetic lethality in BRCA1- or BRCA2-mutant tumour cells and enhances the effects of a PARP inhibitor. Genetic perturbation screening revealed that defects in the 53BP1/Shieldin complex, which cause PARP inhibitor resistance, result in in vitro and in vivo sensitivity to small molecule Polθ polymerase inhibitors. Mechanistically, ART558 increases biomarkers of single-stranded DNA and synthetic lethality in 53BP1-defective cells whilst the inhibition of DNA nucleases that promote end-resection reversed these effects, implicating these in the synthetic lethal mechanism-of-action. Taken together, these observations describe a drug class that elicits BRCA-gene synthetic lethality and PARP inhibitor synergy, as well as targeting a biomarker-defined mechanism of PARPi-resistance.

28 March 2013 in Genome Medicine
Verified
Journal Article
Open access
PDF file
GQGerald Quon
Gerald Quon
SHSyed Haider
Syed Haider
ADAmit G Deshwar
Amit G Deshwar
ACAng Cui
Ang Cui
PBPaul C. Boutros
Paul C. Boutros
QMQuaid Morris
Quaid Morris
Tumor heterogeneity is a limiting factor in cancer treatment and in the discovery of biomarkers to personalize it. We describe a computational purification tool, ISOpure, which directly addresses the effects of variable contamination by normal tissue in clinical tumor specimens. ISOpure uses a set of tumor expression profiles and a panel of healthy tissue expression profiles to generate a purified cancer profile for each tumor sample, and an estimate of the proportion of RNA originating from cancerous cells. Applying ISOpure before identifying gene signatures leads to significant improvements in the prediction of prognosis and other clinical variables in lung and prostate cancer.

8 October 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMatteo Morotti
Matteo Morotti
CZChristos E. Zois
Christos E. Zois
RERokaya El-Ansari
Rokaya El-Ansari
MCMadeleine L. Craze
Madeleine L. Craze
EREmad A. Rakha
Emad A. Rakha
DFDavid Favara
David Favara
Background: Glutamine (Gln) is an abundant nutrient used by cancer cells. Breast cancers cells and particularly triple-receptor negative breast cancer (TNBC) are reported to be dependent on Gln to produce the energy required for survival and proliferation. Despite intense research on the role of the intracellular Gln pathway, few reports have focussed on Gln transporters in breast cancer and TNBC. Methods: The role and localisation of the Gln transporter SLC38A2/SNAT2 in response to Gln deprivation or pharmacological stresses was examined in a panel of breast cancer cell lines. Subsequently, the effect of SLC38A2 knockdown in Gln-sensitive cell lines was analysed. The prognostic value of SLC38A2 in a cohort of breast cancer was determined by immunohistochemistry. Results: SLC38A2 was identified as a strongly expressed amino acid transporter in six breast cancer cell lines. We confirmed an autophagic route of degradation for SLC38A2. SLC38A2 knockdown decreased Gln consumption, inhibited cell growth, induced autophagy and led to ROS production in a subgroup of Gln-sensitive cell lines. High expression of SLC38A2 protein was associated with poor breast cancer specific survival in a large cohort of patients (p = 0.004), particularly in TNBC (p = 0.02). Conclusions: These results position SLC38A2 as a selective target for inhibiting growth of Gln-dependent breast cancer cell lines.

9 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
ZYZhong Y. Yeow
Zhong Y. Yeow
BLBramwell G. Lambrus
Bramwell G. Lambrus
RMRebecca Marlow
Rebecca Marlow
KZKevin H. Zhan
Kevin H. Zhan
MDMary-Anne Durin
Mary-Anne Durin
AHAndrew J. Holland
Andrew J. Holland

21 January 2019 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
CPChristine P’nG
Christine P’nG
JGJeffrey Green
Jeffrey Green
LCLauren C. Chong
Lauren C. Chong
DWDaryl Waggott
Daryl Waggott
SPStephenie Prokopec
Stephenie Prokopec
PBPaul C. Boutros
Paul C. Boutros
We introduce BPG, a framework for generating publication-quality, highly-customizable plots in the R statistical environment. This open-source package includes multiple methods of displaying high-dimensional datasets and facilitates generation of complex multi-panel figures, making it suitable for complex datasets. A web-based interactive tool allows online figure customization, from which R code can be downloaded for integration with computational pipelines. BPG provides a new approach for linking interactive and scripted data visualization and is available at http://labs.oicr.on.ca/boutros-lab/software/bpg or via CRAN at https://cran.r-project.org/web/packages/BoutrosLab.plotting.general

12 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJoseph S. Baxter
Joseph S. Baxter
OLOlivia C. Leavy
Olivia C. Leavy
NDNicola H. Dryden
Nicola H. Dryden
SMSarah Maguire
Sarah Maguire
NJNichola Johnson
Nichola Johnson
OFOlivia Fletcher
Olivia Fletcher
Genome-wide association studies (GWAS) have identified approximately 100 breast cancer risk loci. Translating these findings into a greater understanding of the mechanisms that influence disease risk requires identification of the genes or non-coding RNAs that mediate these associations. Here, we use Capture Hi-C (CHi-C) to annotate 63 loci; we identify 110 putative target genes at 33 loci. To assess the support for these target genes in other data sources we test for associations between levels of expression and SNP genotype (eQTLs), disease-specific survival (DSS), and compare them with somatically mutated cancer genes. 22 putative target genes are eQTLs, 32 are associated with DSS and 14 are somatically mutated in breast, or other, cancers. Identifying the target genes at GWAS risk loci will lead to a greater understanding of the mechanisms that influence breast cancer risk and prognosis.